Introduction: Zoledronic acid (ZA) is a widely used bisphosphonate compound for the prevention of skeletal metastasis-associated osteolysis and treatment of post-menopause osteoporosis. Acute kidney injury is one of the commonly described renal complications. Electrolyte disorder has also been reported relevant to ZA exposure and nephrotoxicity. Syndrome of persistent hypophosphatemia, hypokalemia, and metabolic acidosis is regarded as the initial signs of acute kidney injury.
Case presentation: We reported a 64-year-old female with bone metastasis from lung adenocarcinoma who received a 5-year history of 4-week cycle of ZA infusion. She initially presented with symptomatic severe hypophosphatemia and was finally identified with ZA-induced generalized tubular dysfunction as Fanconi's syndrome and distal renal tubular acidosis. Renal pathological findings revealed toxic renal tubular necrosis. The ZA infusion was thus extended to an 8-week cycle with oral phosphate supplementation and alfacalcidol. Although periodic changes pre- and post-ZA infusion existed yet, hypophosphatemia was effectively improved, and the rapid decline of eGFR was partially delayed. We reviewed the literature and mainly summarized the characteristics of bisphosphonate-associated hypophosphatemia. Moderate hypophosphatemia was more frequently mentioned in contrast to severe cases being predisposed to be reported. Progressive hypophosphatemia serves as an early sign of kidney injury.
Conclusion: Progressive electrolyte disorders and CKD were the long-term renal outcomes of the current patient. We would like to arouse more attention to electrolyte imbalance related to early ZA-induced kidney injury and emphasize the significance of close monitoring.
Keywords: Distal renal tubular acidosis; Hypophosphatemia; Tubular dysfunction; Tubular necrosis; Zoledronic acid.
© 2022 The Author(s). Published by S. Karger AG, Basel.